Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kalaris Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.02M. For fiscal 2025 it was -$38.37M. The highest annual figure on record is -$20.16M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.37M | – |
| FY2024 | Dec 31, 2024 | -$20.67M | – |
| FY2023 | Dec 31, 2023 | -$124.45M | – |
| FY2022 | Dec 31, 2022 | -$142.05M | – |
| FY2021 | Dec 31, 2021 | -$106.32M | – |
| FY2020 | Dec 31, 2020 | -$60.81M | – |
| FY2019 | Dec 31, 2019 | -$20.16M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$30.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.48M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$46.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$36.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.54M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.40M | – |
See a number that looks wrong?